Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENFORCE: GRASPA in Elderly Patients with Newly Diagnosed AML
NCT01810705Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Feb 2013
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
A Phase 2 trial of eryaspase in acute myeloid leukemia (AML), sponsored by PHAXIAM Therapeutics. Started Feb 2013; status: completed.
02
Drugs
eryaspase
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01810705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01810705.